ProQR Therapeutics N.V. (PRQR)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. This filer's financial year end could not be read from its revenue history, so quarters are labelled by the calendar. Amounts in EUR.

Revenue Annual

0 7M 14M 21M 2024: 18.9M 2025: 15.9M 2024 2025

Gross Profit Annual

-45M -30M -15M 0 15M 30M 45M 2024: -31.1M 2025: -43.9M 2024 2025

Revenue minus cost of sales. This filer tags no gross profit of its own..

Operating Income Annual

-45M -30M -15M 0 15M 30M 45M 2024: -30.5M 2025: -43.4M 2024 2025

Net Income Annual

-45M -30M -15M 0 15M 30M 45M 2024: -27.8M 2025: -42.2M 2024 2025

Cost of Revenue Annual

0 25M 50M 75M 2024: 50M 2025: 59.8M 2024 2025

Operating Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M 2024: -36.4M 2025: -52.8M 2024 2025

Free Cash Flow Annual

-60M -40M -20M 0 20M 40M 60M 2024: -37.8M 2025: -53.8M 2024 2025

Operating cash flow minus capital expenditure.

Shares Outstanding Annual

0 40M 80M 120M 2024: 86.1M 2025: 105.3M 2024 2025

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-0.45 -0.30 -0.15 0.00 0.15 0.30 0.45 Q1 '24: -0.33 Q2 '24: -0.26 Q3 '24: -0.29 Q4 '24: -0.31 Q1 '25: -0.32 Q2 '25: -0.41 Q3 '25: -0.41 Q4 '25: -0.40 Q1 '24 Q2 '24 Q3 '24 Q4 '24 Q1 '25 Q2 '25 Q3 '25 Q4 '25

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.